Implant sequence effects in intact male Holstein veal calves: carcass characteristics.
Seven sequences of growth promotant implants were used in intact male Holstein veal calves (n = 443). Implants were administered on d 0 (within 4 d after arrival at the veal barn), 42, and 84. The implants used were placebo (0), Z (36 mg zeranol), ET (20 mg estradiol, 200 mg testosterone), EP/2 (10 mg estradiol, 100 mg progesterone), EP (20 mg estradiol, 200 mg progesterone), and EBA (24 mg estradiol, 120 mg trenbolone acetate). The following sequences were compared: 0-0-0 (negative control), 0-ET-ET, Z-ET-ET, 0-EP-EP, Z-EP-EP, 0-EP/2-EBA, and Z-0-EBA. Sequences 0-EP-EP, Z-EP-EP, and 0-EP/2-EBA increased (P<.05) carcass weight from 3.3 to 3.9% compared to nonimplanted controls. There were no differences (P>.05) in percentage of carcass weight accounted for by the fore vs. rear halves of carcasses, suggesting there was no difference in the distribution of weight. Although there were differences in longissimus area, the results were not consistent, except that there was a trend for longissimus area to be increased by the use of estrogenic-androgenic implants (ET and EBA). There were no differences among implant sequences for carcass conformation, fat cover, muscle texture, marbling/ feathering, muscle color, or muscle chemical composition. Of four implant sequences (0-0-0, 0-ET-ET, 0-EP-EP, and 0-EP/2-EBA) tested for differences in Warner-Bratzler shear force tenderness, the latter two sequences averaged higher (P<.05) for shear force than did the negative control. These results suggest that aggressive implant strategies in young, intact Holstein bull calves (raised as veal) have minimal effects on carcass characteristics.
Wilson
L L
LL
Department of Dairy and Animal Science, The Pennsylvania State University, University Park 16802, USA. LWilson@das.psu.edu
Smith
J L
JL
Swanson
D L
DL
Mills
E W
EW
D000818:Animals; D001835:Body Weight; D002417:Cattle / Q000254:growth & development*; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004435:Eating; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008460:Meat; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology; D014204:Trenbolone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D015029:Zeranol / Q000008:administration & dosage / Q000494:pharmacology
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004968:Estrogens, Non-Steroidal; D012739:Gonadal Steroid Hormones; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D015029:Zeranol; D014204:Trenbolone Acetate